According to the sources provided, there is no information available on the safety of lurbinectedin in pregnant women. The drug is currently approved by the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer in adults who have received prior therapy, but the drug's label warns against its use in pregnancy due to the lack of data on its safety. The label states that lurbinectedin can cause fetal harm when administered to a pregnant woman, and advises healthcare providers to inform pregnant women of the potential risks and benefits of the drug. Additionally, a study published in the Journal of Clinical Oncology [3] states that lurbinectedin is contraindicated in pregnant women, and that women of childbearing potential should use effective contraception during treatment with the drug.

In conclusion, there is no information available on the safety of lurbinectedin in pregnant women. The drug's label warns against its use in pregnancy due to the lack of data on its safety, and healthcare providers are advised to inform pregnant women of the potential risks and benefits of the drug. Women of childbearing potential should use effective contraception during treatment with lurbinectedin.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331752/